目的 通過衛(wèi)生技術(shù)評估新型唑烷酮類抗菌藥康替唑胺，為醫(yī)院遴選、臨床合理使用新型噁唑烷酮藥物提供循證依據(jù)。方法 按照藥品目錄遴選評價管理指南評估細(xì)則對國產(chǎn)康替唑胺片進(jìn)行量化評估，通過檢索中國知網(wǎng)、萬方、維普、PubMed、Metstr等中外文數(shù)據(jù)庫及相關(guān)政府網(wǎng)站獲得康替唑胺的適應(yīng)證、藥理作用、指南推薦情況、藥品價格等信息，按照藥學(xué)特性、有效性、安全性、經(jīng)濟性及其他屬性量化評價，匯總得分并根據(jù)評分劃分推薦級別。結(jié)果 綜合評估結(jié)果顯示，康替唑胺藥學(xué)特性18.8分，有效性15分，安全性14.2分，經(jīng)濟性14分，其他屬性10分，總得分72分，可推薦進(jìn)入醫(yī)療機構(gòu)用藥目錄。結(jié)論 康替唑胺作為新品種可以推薦進(jìn)入醫(yī)療機構(gòu)用藥目錄，對于臨床上利奈唑胺無法治愈的耐甲氧西林金黃色葡萄球菌（MRSA）感染，康替唑胺片有望成為更加安全的抗菌藥物選擇。

Objective To provide evidence-based basis for hospital selection and clinical rational use of new oxazolidone drugs, new antiseptic drug contezolamide was evaluated by health technology. Methods Quantitative evaluation of domestic Contezolid Tablets was carried out according to the evaluation rules of drug catalog selection and evaluation management guidelines. Information of indications, pharmacological effects, guidelines recommendation, drug price, and other information of contezolid were obtained by searching CNKI, Wanfang, VIP, PubMed, Metstr, and other Chinese and foreign databases as well as relevant government websites. According to the quantitative evaluation of pharmaceutical characteristics, efficacy, safety, economy and other attributes, the scores were summarized and the recommendation levels were divided according to the scores. Results The comprehensive evaluation results showed that contezolamide scored 18.8 points for pharmaceutical characteristics, 15 points for effectiveness, 14.2 points for safety, 14 points for economy and 10 points for other attributes, with a total score of 72 points, which can be recommended to be included in the drug list of medical institutions. Conclusion As a new product, contezolid can be recommended to enter the drug catalog of medical institutions. For the methicillin-resistant Staphylococcus aureus (MRSA) infection that cannot be cured by linezolid clinically, Contezolid Tablets are expected to become a safer antibacterial drug choice.

R978.1